Literature DB >> 22728874

Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.

Zhipeng Meng1, Xiaoqiong Wang, Yichao Gan, Yunfeng Zhang, Hong Zhou, Carl Van Ness, Jun Wu, Guiyu Lou, Hua Yu, Chao He, Rongzhen Xu, Wendong Huang.   

Abstract

BACKGROUND & AIMS: Liver tumor, especially hepatocellular carcinoma (HCC), is closely associated with chronic inflammation. We previously showed that farnesoid X receptor knockout (FXR(-)(/)(-)) mice displayed chronic inflammation and developed spontaneous liver tumors when they aged. However, the mechanism by which inflammation leads to HCC in the absence of FXR is unclear. Because IFNγ is one of the most upregulated pro-inflammatory cytokines in FXR(-)(/)(-) livers, we generated IFNγ(-)(/)(-)FXR(-)(/)(-) double knockout mice to determine IFNγ's roles in hepatocarcinogenesis.
METHODS: IFNγ(-)(/)(-) mice were crossed with an FXR(-)(/)(-) C57BL/6 background or injected i.p. with the hepatocarcinogen diethylnitrosamine (DEN). Hepatocarcinogenesis was analyzed with biochemical and histological methods.
RESULTS: IFNγ deletion accelerated spontaneous hepatocarcinogenesis in FXR(-)(/)(-) mice and increased the susceptibility to DEN-induced hepatocarcinogenesis. IFNγ deletion enhanced activation of HCC promoters STAT3 and JNK/c-Jun, but abolished induction of p53 in IFNγ(-)(/)(-) livers after acute DEN-induced injury. Furthermore, hepatic p53 expression increased in aged wild type mice but not in aged IFNγ(-)(/)(-) and IFNγ(-)(/)(-)FXR(-)(/)(-) mice, while activation of STAT3 and JNK/c-Jun was enhanced in aged IFNγ(-)(/)(-) and IFNγ(-)(/)(-)FXR(-)(/)(-) mice. In addition, IFNγ inhibited liver cancer xenograft growth and impaired IL-6-induced STAT3 phosphorylation by inducing SOCS1/3 expression.
CONCLUSIONS: Increased IFNγ expression in FXR(-)(/)(-) livers represents a protective response of the liver against chronic injury and tumorigenesis. IFNγ suppresses hepatocarcinogenesis by inducing p53 expression and preventing STAT3 activation.
Copyright © 2012 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22728874      PMCID: PMC3477276          DOI: 10.1016/j.jhep.2012.06.016

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  46 in total

Review 1.  Immunity, inflammation, and cancer.

Authors:  Sergei I Grivennikov; Florian R Greten; Michael Karin
Journal:  Cell       Date:  2010-03-19       Impact factor: 41.582

Review 2.  NF-κB and STAT3 - key players in liver inflammation and cancer.

Authors:  Guobin He; Michael Karin
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

3.  The bile acid sensor farnesoid X receptor is a modulator of liver immunity in a rodent model of acute hepatitis.

Authors:  Andrea Mencarelli; Barbara Renga; Marco Migliorati; Sabrina Cipriani; Eleonora Distrutti; Luca Santucci; Stefano Fiorucci
Journal:  J Immunol       Date:  2009-10-30       Impact factor: 5.422

4.  FXR regulates liver repair after CCl4-induced toxic injury.

Authors:  Zhipeng Meng; Yandong Wang; Lin Wang; Wen Jin; Nian Liu; Hao Pan; Lucy Liu; Lawrence Wagman; Barry M Forman; Wendong Huang
Journal:  Mol Endocrinol       Date:  2010-03-08

5.  Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation.

Authors:  Guobin He; Guann-Yi Yu; Vladislav Temkin; Hisanobu Ogata; Christian Kuntzen; Toshiharu Sakurai; Wolfgang Sieghart; Markus Peck-Radosavljevic; Hyam L Leffert; Michael Karin
Journal:  Cancer Cell       Date:  2010-03-16       Impact factor: 31.743

6.  The Hippo-Salvador pathway restrains hepatic oval cell proliferation, liver size, and liver tumorigenesis.

Authors:  Kwang-Pyo Lee; Joo-Hyeon Lee; Tae-Shin Kim; Tack-Hoon Kim; Hee-Dong Park; Jin-Seok Byun; Min-Chul Kim; Won-Il Jeong; Diego F Calvisi; Jin-Man Kim; Dae-Sik Lim
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

7.  Interferon gamma attenuates insulin signaling, lipid storage, and differentiation in human adipocytes via activation of the JAK/STAT pathway.

Authors:  Fiona C McGillicuddy; Elise H Chiquoine; Christine C Hinkle; Roy J Kim; Rachana Shah; Helen M Roche; Emer M Smyth; Muredach P Reilly
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

Review 8.  Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases.

Authors:  Xiaoyu Hu; Lionel B Ivashkiv
Journal:  Immunity       Date:  2009-10-16       Impact factor: 31.745

9.  The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-beta signaling.

Authors:  L Lin; R Amin; G I Gallicano; E Glasgow; W Jogunoori; J M Jessup; M Zasloff; J L Marshall; K Shetty; L Johnson; L Mishra; A R He
Journal:  Oncogene       Date:  2009-01-12       Impact factor: 9.867

10.  Plasma levels of interferon-gamma correlate with age-related disturbances of circadian rhythms and survival in a non-human primate.

Authors:  Florence Cayetanot; Mikael Nygård; Martine Perret; Krister Kristensson; Fabienne Aujard
Journal:  Chronobiol Int       Date:  2009-12       Impact factor: 2.877

View more
  13 in total

Review 1.  STAT3 in hepatocellular carcinoma: new perspectives.

Authors:  Jasmin Svinka; Wolfgang Mikulits; Robert Eferl
Journal:  Hepat Oncol       Date:  2013-12-20

Review 2.  FXR and liver carcinogenesis.

Authors:  Xiong-fei Huang; Wei-yu Zhao; Wen-dong Huang
Journal:  Acta Pharmacol Sin       Date:  2014-12-15       Impact factor: 6.150

3.  Pleiotropic roles of FXR in liver and colorectal cancers.

Authors:  Xiongfei Huang; Mingjie Fan; Wendong Huang
Journal:  Mol Cell Endocrinol       Date:  2022-01-04       Impact factor: 4.102

4.  Mechanisms of STAT3 activation in the liver of FXR knockout mice.

Authors:  Guodong Li; Yan Zhu; Ossama Tawfik; Bo Kong; Jessica A Williams; Le Zhan; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2013-10-03       Impact factor: 4.052

5.  Bile Acid Receptors and Liver Cancer.

Authors:  Xichun Wang; Xianghui Fu; Carl Van Ness; Zhipeng Meng; Xiaoxiao Ma; Wendong Huang
Journal:  Curr Pathobiol Rep       Date:  2012-12-21

6.  Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.

Authors:  Guodong Li; Bo Kong; Yan Zhu; Le Zhan; Jessica A Williams; Ossama Tawfik; Karen M Kassel; James P Luyendyk; Li Wang; Grace L Guo
Journal:  Toxicol Appl Pharmacol       Date:  2013-06-26       Impact factor: 4.219

7.  Long non-coding RNA00364 represses hepatocellular carcinoma cell proliferation via modulating p-STAT3-IFIT2 signaling axis.

Authors:  Wei-Guo Tang; Bo Hu; Hai-Xiang Sun; Qi-Man Sun; Chao Sun; Pei-Yao Fu; Zhang-Fu Yang; Xin Zhang; Chen-Hao Zhou; Jia Fan; Ning Ren; Yang Xu
Journal:  Oncotarget       Date:  2017-10-25

8.  CAMK2γ antagonizes mTORC1 activation during hepatocarcinogenesis.

Authors:  Z Meng; X Ma; J Du; X Wang; M He; Y Gu; J Zhang; W Han; Z Fang; X Gan; C Van Ness; X Fu; D E Schones; R Xu; W Huang
Journal:  Oncogene       Date:  2016-11-07       Impact factor: 9.867

9.  T lymphocyte SHP2-deficiency triggers anti-tumor immunity to inhibit colitis-associated cancer in mice.

Authors:  Wen Liu; Wenjie Guo; Lihong Shen; Zhen Chen; Qiong Luo; Xiaolin Luo; GenSheng Feng; Yongqian Shu; Yanhong Gu; Qiang Xu; Yang Sun
Journal:  Oncotarget       Date:  2017-01-31

10.  FXR induces SOCS3 and suppresses hepatocellular carcinoma.

Authors:  Fei Guo; Zhizhen Xu; Yan Zhang; Peng Jiang; Gang Huang; Shan Chen; Xilin Lyu; Ping Zheng; Xin Zhao; Yijun Zeng; Shuguang Wang; Fengtian He
Journal:  Oncotarget       Date:  2015-10-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.